Enfortumab vedotin: all 59 studies that test it

Page 1 of 1. Open to participants first (37), then studies with results posted, then the rest; newest registration first within each.

• A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingNCT07890714Phase 1/2
• Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingNCT07863765Phase 2
• Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingNCT07825753Phase 2
• A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingNCT07822373Phase 2
• Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingNCT07667335Phase 1/2
• EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBCRecruitingNCT07647289Phase 2
• Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)Not yet recruitingNCT07629700Not applicable
• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingNCT07566156Phase 3
• Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerRecruitingNCT07484022Phase 1
• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingNCT07475806Phase 2
• Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingNCT07421700Phase 1/2
• SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaNot yet recruitingNCT07374549Phase 2
• Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination TherapyRecruitingNCT07347314Phase 2
• Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaRecruitingNCT07221942Phase 2
• N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingNCT07217496Phase 1
• Circulating Tumor DNA Response In Urothelial CancerRecruitingNCT07183319Phase 2
• Study of EV for Recurrent Endometrial CarcinomaRecruitingNCT07139977Phase 2
• DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingNCT07110038Phase 2
• Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersRecruitingNCT07087860Phase 2
• A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaRecruitingNCT06891560Phase 2
• A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerRecruitingNCT06862219Phase 4
• Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingNCT06809140Phase 2
• Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialRecruitingNCT06764095Phase 4
• Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCCRecruitingNCT06553885Phase 2
• Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingNCT06470282Phase 1/2
• Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)RecruitingNCT06434350Phase 1/2
• Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder CancerRecruitingNCT06394570Phase 1/2
• Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingNCT06356155Phase 2
• Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingNCT06311214Phase 2
• Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary CarcinomaRecruitingNCT06302569Phase 2
• Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
• Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the PenisRecruitingNCT06104618Phase 2
• Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)RecruitingNCT05879653Phase 2
• Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerRecruitingNCT05775471Phase 2
• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingNCT05756569Phase 2
• Renal Retention in High Grade Upper Tract Urothelial CancerRecruitingNCT05656235Phase 2
• Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CancerRecruitingNCT04878029Phase 1
• A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor TherapyCompletedNCT04995419Phase 2Results posted
• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial CancerActive, not recruitingNCT04223856Phase 3Results posted
• Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)Active, not recruitingNCT03924895Phase 3Results posted
• Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)CompletedNCT03474107Phase 3Results posted
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03219333Phase 2Results posted
• PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma PatientsActive, not recruitingNCT06906822Phase 2
• A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Active, not recruitingNCT06305767Phase 1/2
• Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)Active, not recruitingNCT05915351Phase 2
• A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary TractActive, not recruitingNCT05868265Phase 2
• A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)CompletedNCT05524545Phase 1
• Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerActive, not recruitingNCT05239624Phase 2
• StrataPATH™ (Precision Indications for Approved Therapies)TerminatedNCT05097599Phase 2
• A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT05014139Phase 1
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3
• Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04754191Phase 2
• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Active, not recruitingNCT04700124Phase 3
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2
• A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT03070990Phase 1
• A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4CompletedNCT02091999Phase 1
• A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4CompletedNCT01409135Phase 1

← Enfortumab vedotin overview